| Literature DB >> 32481550 |
Na-Hyun Kim1, Jonghwan Jegal2, Yun Na Kim3, Jeong-Doo Heo1, Jung-Rae Rho4, Min Hye Yang2, Eun Ju Jeong3.
Abstract
This study aimed to investigate the beneficial effects of A. melanocarpa on testosterone propionate (TP)-induced benign prostatic hyperplasia (BPH) in Wistar rats. Moreover, the bioactive constituents in the extract were determined using LC/MS and HPLC analyses. The dried fruits of A. melanocarpa were extracted using accelerated solvent extraction (ASE) under different extract conditions (temperature, 30 C or 100 C; extract solvent, 60% or 100% ethanol) to yield four extracts (T1~T4). Of the four A. melanocarpa extracts, T1 extracted under the condition of 100% ethanol/low temperature (30 C) exhibited the greatest inhibitory activity on TP-induced prostatic hyperplasia in rats. The administration of T1 (100 mg/kg body weight, p.o.) for six weeks attenuated TP-induced prostate enlargement and reduced the levels of dihydrotestosterone (DHT) and 5α-reductase in both serum and prostate tissue. The suppression of PCNA mRNA expression in prostate tissue was remarkable in T1-treated rats. In LC/MS analysis, the levels of main anthocyanins and phenolics were significantly higher in T1 than in the other extracts. Furthermore, the quantitative study showed that the contents of cyanidin-3-glucose and cyanidin-3-xylose in T1 exhibited 1.27~1.67 and 1.10~1.26 folds higher compared to those in the other extracts. These findings demonstrated that A. melanocarpa extract containing anthocyanins as bioactive constituents attenuated the development of testosterone-induced prostatic hyperplasia, and suggested that this extract has therapeutic potential to treat prostate enlargement and BPH.Entities:
Keywords: 5-alpha-reductase; Aronia melanocarpa; androgen receptor; benign prostatic hyperplasia; constituents; testosterone
Mesh:
Substances:
Year: 2020 PMID: 32481550 PMCID: PMC7352698 DOI: 10.3390/nu12061575
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Effects of orally administered A. melanocarpa extracts, T1~T4 on prostate weights and prostate indices of testosterone propionate-treated Wistar rats. Clinical features of TP-induced prostate hyperplasia; Bar = 10 mm (a), absolute prostate weights (b), and prostate indices (c). Results were expressed as the mean value (± SD) of animals in each group. # p < 0.001 vs. the sham group; * p < 0.05 vs. the VC group. Sham, non-BPH-induced and received 0.5% CMC-Na; VC, BPH-induced and received 0.5% CMC-Na; PC, BPH-induced and saw palmetto-treated group. The preparation and administration of T1~T4 are described in Materials and Methods.
Serum biochemistry data at necropsy for all experimental groups of rats.
| TP | ALB | BUN | CREA | AST | ALT | ALP | Bil | TG | TCHO | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sham | 5.4 ± 0.1 | 3.3 ± 0.1 | 20.4 ± 0.5 | 0.50 ± 0.05 | 123.1 ± 10.4 | 34.3 ± 5.8 | 485.5 ± 68.9 | 0.16 ± 0.03 | 114.7 ± 33.1 | 73.7 ± 4.4 |
| VC | 6.3 ± 0.9 | 4.1 ± 0.5 | 25.2 ± 4.3 | 0.56 ± 0.10 | 134.2 ± 22.5 | 33.7 ± 7.9 | 530.8 ± 110.3 | 0.17 ± 0.03 | 99.9 ± 33.6 | 86.6 ± 18.4 |
| PC | 6.5 ± 0.6 | 4.1 ± 0.3 | 25.0 ± 2.0 | 0.51 ± 0.05 | 132.4 ± 11.5 | 36.5 ± 5.5 | 595.8 ± 128.4 | 0.14 ± 0.04 | 130.7 ± 51.2 | 87.8 ± 21.8 |
| T1 | 5.7 ± 0.1 | 3.8 ± 0.1 | 23.4 ± 2.6 | 0.52 ± 0.03 | 94.1 ± 8.7 * | 31.9 ± 2.8 | 517.4 ± 103.3 | 0.17 ± 0.01 | 79.0 ± 26.9 | 78.4 ± 6.6 |
| T2 | 5.7 ± 0.1 | 3.7 ± 0.1 | 21.4 ± 0.8 | 0.50 ± 0.09 | 100.6 ± 8.1 * | 34.0 ± 3.3 | 435.3 ± 91.8 | 0.16 ± 0.03 | 113.3 ± 57.3 | 83.0 ± 9.4 |
| T3 | 5.8 ± 0.2 | 3.8 ± 0.1 | 22.7 ± 2.2 | 0.52 ± 0.06 | 96.3 ± 8.0 * | 31.6 ± 3.6 | 469.2 ± 91.9 | 0.16 ± 0.02 | 123.9 ± 59.3 | 74.8 ± 12.7 |
| T4 | 5.6 ± 0.2 | 3.7 ± 0.2 | 20.1 ± 1.3 | 0.44 ± 0.03 | 82.5 ± 19.4 * | 32.6 ± 2.1 | 358.8 ± 37.1* | 0.18 ± 0.02 | 72.3 ± 19.9 | 73.8 ± 6.8 |
Serum levels of total protein (TP), albumin (ALB), blood urea nitrogen (BUN), creatinine (CREA), aspartate transaminase (AST) alanine transaminase (ALT), alkaline phosphatase (ALP) total bilirubin (Bil), triglyceride (TG), and total cholesterol (TCHO) was indicated as the mean value (± SD) of animals in each group. * p < 0.05 vs. the VC group. Sham, non-BPH-induced and received 0.5% CMC-Na; VC, BPH-induced and received 0.5% CMC-Na; PC, BPH-induced and saw palmetto-treated group.
Figure 2Effects of orally administered A. melanocarpa extracts T1~T4 on dihydrotestosterone (DHT) and 5α-reductase levels in prostate tissues and sera of testosterone propionate-treated Wistar rats. DHT levels in prostate (a), 5α-reductase levels in prostate (b), DHT levels in serum (c), and 5α-reductase levels in serum (d). Results were expressed as the mean value (± SD) of animals in each group. # p < 0.01 vs. the sham group; * p < 0.05 vs. the VC group. The preparation and administration of T1~T4 are described in Materials and Methods.
Figure 3Effects of orally administered A. melanocarpa extracts T1~T4 on androgen receptor (AR), prostate specific antigen (PSA), and proliferating cell nuclear antigen (PCNA) protein expressions in the ventral prostate tissues of testosterone propionate-treated Wistar rats. AR mRNA expressions (a), PSA mRNA expressions (b), and PCNA mRNA expressions (c). Results were expressed as the mean value (± SD) of animals in each groups. * p < 0.05 vs. the VC group. The preparation and administration of T1~T4 are described in Materials and Methods.
Relative composition of phenolic compounds in four A. melanocarpa extracts (T1~T4) as determined by LC/MS.
| Cyn-Hex | Cyn-Ara | Cyn-Pent | Cyn | CQ1 | CQ2 | QV | |
|---|---|---|---|---|---|---|---|
| (× 103) | |||||||
| T1 | 586 | 158 | 2.09 | 47.7 | 3.07 | 5.73 | 13.2 |
| T2 | 268 | 68 | 1.08 | 20.9 | 2.21 | 3.55 | 10 |
| T3 | 310 | 80.9 | 1.13 | 25.7 | 2.76 | 4.24 | 10.9 |
| T4 | 230 | 56.8 | 0.69 | 18.4 | 2.45 | 3.86 | 0.88 |
T1, 100% ethanol/low temperature (30 °C) extract; T2, 100% ethanol/high temperature (100 °C) extract; T3, 60% ethanol/low temperature (30 °C) extract; T4, 60% ethanol/high temperature (100 °C) extract; Cyn-Hex: cyanidin-hexose, Cyn-Ara, cyanidin-3-arabinose; Cyn-Pen, cyanidin-3-pentose, Cyn, cyanidin, CQ1, caffeonylquinic acid; CQ2, caffeonylquinic acid; QV, quercetin vicianoside.
Figure 4Chemical structures of compounds detected in LC/MS
Figure 5Chemical structures of compounds isolated from A. melanocarpa fruits
Content of phenolic compounds in four A. melanocarpa extracts (T1~T4) as determined by HPLC.
| Sample | Contents (mg/mL) | |||
|---|---|---|---|---|
| 1-(3, 4-Dihydroxycinnamoyl Cyclopenta-2, 3-dilo) | Methyl 3-O-Caffeoylquinic Acid | Cyanidin-3-Glucoside | Cyanidin-3-Xyloside | |
| T1 | 0.5349 | ND | 0.7642 | 2.6843 |
| T2 | 0.5461 | ND | 0.5107 | 2.3228 |
| T3 | 0.5015 | ND | 0.4559 | 2.1206 |
| T4 | 0.5583 | ND | 0.6002 | 2.4279 |
T1, 100% ethanol/low temperature (30 °C) extract; T2, 100% ethanol/high temperature (100 °C) extract; T3, 60% ethanol/low temperature (30 °C) extract; T4, 60% ethanol/high temperature (100 °C) extract, ND: not detected.